1,789 results match your criteria Nonseminomatous Testicular Tumors


Gastrointestinal bleeding caused by metastatic testicular choriocarcinoma: a case report and literature review.

World J Surg Oncol 2022 Jun 16;20(1):205. Epub 2022 Jun 16.

Department of Gastroenterology and Hepatology, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Background: Testicular tumor is one of the common solid tumors in young men. Testicular choriocarcinoma is a non-spermatogonial germ cell tumor, which is the rarest of all testicular cancers. Choriocarcinoma usually shows bleeding at the metastatic site, while gastrointestinal involvement is rare. Read More

View Article and Full-Text PDF

Safety of Minimizing Intensity of Follow-up on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors.

Eur Urol Open Sci 2022 Jun 27;40:46-53. Epub 2022 Apr 27.

Department of Surgery (Urology), Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Background: We have recommended active surveillance as the preferred management option for clinical stage I (CSI) testicular germ cell tumors (GCTs) since 1980. Over time, the recommended intensity of surveillance has decreased; however, the impact on relapse detection has not been investigated.

Objective: To examine relapse rate, time to relapse, extent of disease, and burden of treatment at relapse across decreasing surveillance intensity over time. Read More

View Article and Full-Text PDF

Peri-treatment adverse events of primary mediastinal non-seminomatous germ cell tumors.

Pediatr Blood Cancer 2022 Aug 20;69(8):e29781. Epub 2022 May 20.

Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan.

Primary mediastinal non-seminomatous germ cell tumors (PMNSGCT) are rare but life-threatening thoracic cancers. We report our experience from eight patients with peri-treatment adverse events. By analyzing changes in tumor extent, serum tumor markers, and pathologies between diagnosis and transfer, those events could be attributed to postbiopsy respiratory insufficiency, growing teratoma syndrome, secondary histiocytic malignancy, and PMNSGCT progression. Read More

View Article and Full-Text PDF

Metastatic Potential of Small Testicular Germ Cell Tumors: Implications for Surveillance of Small Testicular Masses.

Eur Urol Open Sci 2022 Jun 26;40:16-18. Epub 2022 Apr 26.

Department of Medical Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

Incidental detection of urogenital tumors has increased in recent decades owing to the greater use of ultrasonography and cross-sectional imaging. For patients with low-risk prostate cancer or small renal masses, active surveillance represents a valid treatment option. Similarly, for men with small testicular masses <10 mm, active surveillance has been discussed as an alternative to surgery, although little is known regarding the behavior of small testicular germ cell tumors (GCTs). Read More

View Article and Full-Text PDF

Severe thyrotoxicosis as initial presentation of gastric choriocarcinoma: a case report.

J Med Case Rep 2022 Apr 21;16(1):159. Epub 2022 Apr 21.

Department of Surgical and Molecular Pathology, American British Cowdray Medical Center, Mexico City, Mexico.

Background: Extragonadal choriocarcinoma is rare and can be associated with hyperthyroidism when producing very high levels of human chorionic gonadotropin.

Case Presentation: A 62-year-old Hispanic female presented with a 3-week history of shortness of breath, palpitations, extreme weakness, new-onset hot flashes, and right flank pain. Her physical examination was remarkable for tachycardia, hepatomegaly, hyperreflexia, and tremor; goiter was absent. Read More

View Article and Full-Text PDF

Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study.

Ther Adv Med Oncol 2022 31;14:17588359221086813. Epub 2022 Mar 31.

Department of Medical Oncology, Wilhelminenspital, Vienna, Austria.

Introduction: Clinical stage 1 (CS1) nonseminomatous (NS) germ cell tumors involve a 30% probability of relapse upon surveillance. Adjuvant chemotherapy with one course of bleomycin, etoposide, and cisplatin (1xBEP) can reduce this risk to <5%. However, 1xBEP results are based solely on five controlled trials from high-volume centers. Read More

View Article and Full-Text PDF

Surgical Resection of a Third Ventricle Nongerminomatous Germ Cell Tumor: Two-Dimensional Operative Video.

World Neurosurg 2022 Jul 30;163. Epub 2022 Mar 30.

Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China; National Center for Neurological Disorders, Shanghai, China; Neurosurgical Institute of Fudan University, Shanghai, China; Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China; State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, School of Basic Medical Sciences and Institutes of Brain Science, Fudan University, Shanghai, China; Research Unit of New Technologies of Micro-Endoscopy Combination in Skull Base Surgery (2018RU008), Chinese Academy of Medical Sciences, Shanghai, China; Department of Neurosurgery, Fujian Campus of National Regional Medical Center, Huashan Hospital, Fudan University, Fuzhou, Fujian, China. Electronic address:

Surgical resection of a pineal tumor growing into the third ventricle is difficult owing to the complex neurovascular structures, and nongerminomatous germ cell tumor is the most common malignant tumor in pediatric patients. Removing the tumor efficiently with minimal blood loss while protecting the surrounding neurovascular structure is challenging. We present a surgical case of a 9-year-old patient with a third ventricle nongerminomatous germ cell tumor (Video). Read More

View Article and Full-Text PDF

Delivering Chemotherapy to a Metastatic Poor Risk Testicular Cancer Patient on Hemodialysis.

Curr Oncol 2022 03 8;29(3):1808-1812. Epub 2022 Mar 8.

Department of Urology, Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, NS 6299, Canada.

A standard curative intent approach of chemotherapy treatment for metastatic testicular cancer has been well established. However, there is little guidance for patients undergoing hemodialysis (HD) who require chemotherapy for this disease. Thus, we describe our treatment approach and rationale for a patient on HD with poor risk metastatic nonseminomatous germ cell tumor involving the testicle, lymph nodes, liver, and bone. Read More

View Article and Full-Text PDF

The core four - A panel of immunohistochemistry markers to diagnose and subtype testicular germ cell tumors.

Urol Ann 2022 Jan-Mar;14(1):21-26. Epub 2021 Dec 28.

Department of Pathology and Lab Medicine, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, India.

Context: Immunohistochemistry (IHC) to differentiate germ cell tumors.

Aims: The aim of the study is to differentiate seminomatous and nonseminomatous germ cell tumors (GCTs) with morphological overlap using a minimal and affordable panel of IHC markers.

Settings And Design: This is a retrospective observational study. Read More

View Article and Full-Text PDF
December 2021

New Landmarks Towards Reducing the Treatment Burden for Patients with a Postchemotherapy Residual Retroperitoneal Mass from Nonseminomatous Germ-cell Testicular Tumors.

Eur Urol Oncol 2022 04 17;5(2):244-245. Epub 2022 Feb 17.

Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Università degli Studi di Milano, Milan, Italy.

View Article and Full-Text PDF

Survival of nonseminomatous germ cell tumors in pediatric patients and young adults - A stage group stratified analysis.

Urol Oncol 2022 04 8;40(4):169.e1-169.e12. Epub 2022 Feb 8.

Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.

Introduction: Testicular germ cell tumors, particularly nonseminomatous germ cell tumors (NSGCT), comprise the most common solid malignancy in male children and younger adults. While these patients experience excellent survival outcomes, few studies have characterized their survival by age. Thus, we aimed to characterize the relative survival of NSGCT by age, stratifying patients by stage group. Read More

View Article and Full-Text PDF

Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor.

Oncology (Williston Park) 2021 12 17;35(12):816-819. Epub 2021 Dec 17.

Hematology-Oncology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.

The case An 18-year-old male presented with a one-month history of a nonpainful right testicular enlargement. He had no family history of neoplasia, nor any relevant past medical history. The physical examination was only remarkable for an enlarged right testicle. Read More

View Article and Full-Text PDF
December 2021

Testicular tumors: discriminative value of conventional MRI and diffusion weighted imaging.

Medicine (Baltimore) 2021 Dec;100(48):e27799

Department of Medical Imaging, The Affiliated Hospital of Jining Medical University, Jining, China.

Abstract: To explore the feasibility of using conventional MRI features combined with apparent diffusion coefficient (ADC) values for the differential diagnosis of testicular tumors.A total of 63 patients with pathologically confirmed testicular tumors were enrolled in this study. In particular, there were 46 cases of malignant lesions and 17 cases of benign lesions. Read More

View Article and Full-Text PDF
December 2021

A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors.

Int J Radiat Oncol Biol Phys 2022 05 4;113(1):143-151. Epub 2022 Jan 4.

Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

Purpose: Children's Oncology Group study ACNS1123 tested the efficacy of reduced dose and field of radiation therapy (RT) for patients with localized nongerminomatous germ cell tumors (NGGCT) who achieved a complete (CR) or partial response (PR) to chemotherapy. Here, we evaluate the quality of RT and patterns of failure for patients eligible for reduced RT in this phase 2 trial.

Methods And Materials: Patients with localized NGGCT with CR/PR after induction chemotherapy received reduced RT to 30. Read More

View Article and Full-Text PDF

Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer.

J Urol 2022 05 3;207(5):1057-1066. Epub 2022 Jan 3.

Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.

Purpose: Retroperitoneal lymph node dissection (RPLND) for men with clinical stage (CS) I or II testicular nonseminomatous germ cell tumor (NSGCT) has both staging and therapeutic implications. We aimed to investigate the impact of lymph node count (LNC) on outcome after primary RPLND for men with CS I or II NSGCT using a nationally representative data set.

Materials And Methods: A retrospective analysis of men who received a primary RPLND for CS I or II NSGCT was performed using the National Cancer Database. Read More

View Article and Full-Text PDF

Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia In Situ, and Germ Cell Tumors of the Testis.

Am J Clin Pathol 2022 05;157(5):644-648

Department of Pathology, Maggiore Hospital, AUSL-Bologna, Bologna, Italy.

Objectives: Preferentially expressed antigen in melanoma (PRAME) has a key role in regulating pluripotency of primordial germ cells and in the development of germ cell tumors of the testis (GCTT). However, its immunohistochemical expression in normal testes and its neoplastic counterpart remain largely unknown.

Methods: We retrospectively investigated the expression of PRAME in 26 cases of GCTT, 21 cases of germ cell neoplasia in situ (GCNIS), and 17 cases of uninvolved background testes. Read More

View Article and Full-Text PDF

Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1.

World J Urol 2022 Feb 14;40(2):317-326. Epub 2021 Nov 14.

Faculty of Biology and Chemistry, University Bremen, Leobener Strasse 2/FVG, 28359, Bremen, Germany.

Purpose: Lymphovascular invasion (LV1) and presence of > 50% embryonal carcinoma (> 50% EC) represent risk factors for progression in patients with clinical stage 1 (CS1) nonseminomatous (NS) testicular germ cell tumours. As serum levels of microRNA-371a-3p (M371) are capable of detecting small amounts of GCT, we evaluated if LV1 and > 50% EC are associated with M371 levels.

Methods: M371 serum levels were measured postoperatively in 153 NS CS1 patients and both pre- and postoperatively in 131 patients. Read More

View Article and Full-Text PDF
February 2022

Successful treatment of radiotherapy and apatinib in patient with mediastinal mixed non-seminomatous germ cell tumor: A case report.

Medicine (Baltimore) 2021 Oct;100(43):e27617

Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China.

Rationale: Mediastinal non-seminomatous germ cell tumors (MNSGCTs) are rare malignancies. Chemotherapy followed by surgical resection has been regarded as the standard management, but treatment options for chemotherapy-refractory patients or those with unresectable tumors are limited, resulting in a very poor prognosis.

Patient Concerns: An 18-year-old female presented with symptoms of cough, chest tightness, and shortness of breath for 2 months, and the symptoms gradually worsened. Read More

View Article and Full-Text PDF
October 2021

12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors.

Neuro Oncol 2022 May;24(5):834-846

Division of Brain Tumor Translational Research, National Cancer Center Research Institute, Tokyo, Japan.

Background: Central nervous system (CNS) germ cell tumors (GCTs) are neoplasms predominantly arising in pediatric and young adult populations. While germinomas generally respond to chemotherapy and radiation, non-germinomatous GCTs (NGGCTs) require more intensive treatment. This study aimed to determine whether 12p gain could predict the prognosis of CNS GCTs. Read More

View Article and Full-Text PDF

Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications.

Cancers (Basel) 2021 Oct 18;13(20). Epub 2021 Oct 18.

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Via P. Maroncelli 40, 47014 Meldola, Italy.

Mediastinal germ cell tumors (MGCTs) share histologic, molecular and biomarkers features with testicular GCTs; however, nonseminomatous MGCTs are usually more aggressive and have poorer prognosis than nonseminomatous TGCTs. Most nonseminomatous MGCT cases show early resistance to platinum-based therapies and seldom have been associated with the onset of one or more concomitant somatic malignancies, in particular myeloid neoplasms with recent findings supporting a common, shared genetic precursor with the primary MGCT. Genomic, transcriptomic and epigenetic features of testicular GCTs have been extensively studied, allowing for the understanding of GCT development and transformation of seminomatous and nonseminomatous histologies. Read More

View Article and Full-Text PDF
October 2021

A Rare Diagnosis with Poor Prognosis: Primary Gastric Choriocarcinoma.

Am J Med Sci 2022 03 19;363(3):e27-e28. Epub 2021 Oct 19.

Division of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Electronic address:

View Article and Full-Text PDF

Survival outcomes, hematologic complications and growth impairment after sequential chemoradiotherapy in intracranial NGGCTs: a retrospective study.

Strahlenther Onkol 2022 05 21;198(5):458-467. Epub 2021 Oct 21.

Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 510515, Guangzhou, China.

Purpose: This study aimed to evaluate the clinical features, prognostic factors, and survival outcomes for patients with intracranial nongerminomatous germ cell tumors (NGGCTs), with a particular focus on treatment toxicity for long-term survivors.

Methods: Intracranial NGGCTs treated with platinum-based chemotherapy and craniospinal irradiation (CSI) in our institution were retrospectively analyzed. Hematological complications following sequential chemoradiotherapy as well as height and weight in childhood survivors were evaluated. Read More

View Article and Full-Text PDF

A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections.

World J Urol 2022 Jan 1;40(1):119-126. Epub 2021 Oct 1.

Department of Urology, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK.

Purpose: To describe and compare differences in peri-operative outcomes of robot-assisted (RA-RPLND) and open (O-RPLND) retroperitoneal lymph node dissection performed by a single surgeon where chemotherapy is the standard initial treatment for Stage 2 or greater non-seminomatous germ cell tumour.

Methods: Review of a prospective database of all RA-RPLNDs (28 patients) and O-RPLNDs (72 patients) performed by a single surgeon from 2014 to 2020. Peri-operative outcomes were compared for patients having RA-RPLND to all O-RPLNDs and a matched cohort of patients having O-RPLND (20 patients). Read More

View Article and Full-Text PDF
January 2022

Testicular Germ Cell Tumors: Classification, Pathologic Features, Imaging Findings, and Management.

Radiographics 2021 Oct;41(6):1698-1716

From the Departments of Radiology (V.S.K., D.V.Z., R.A.M.) and Pathology (A.N.), University of Texas Health at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229; Department of Radiology, University of Texas M. D. Anderson Cancer Center, Houston, Tex (D.G., S.R.P.); and Department of Radiology, University of Texas Health at Houston, Houston, Tex (V.T.).

Testicular germ cell tumors (TGCTs) demonstrate a wide variety of histopathologic, genetic, pathogenetic, and immunocytochemical characteristics and various clinical-biologic profiles and prognoses. Most TGCTs arise from an intratubular precursor cell referred to as germ cell neoplasia in situ (GCNIS), which is an embryonic germ cell with the potential to differentiate into a plethora of embryonic and extraembryonic lineages. Advances in pathologic examination and genetics paved the way for the 2016 World Health Organization (WHO) classification system, which recognizes two pathogenetically distinct groups of TGCTs. Read More

View Article and Full-Text PDF
October 2021

Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors.

Pediatr Blood Cancer 2022 01 24;69(1):e29365. Epub 2021 Sep 24.

The Division of Hematology, Oncology and BMT, The Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.

We aimed toidentify prognostic factors that may help better understand the behavior of relapsed central nervous system nongerminomatous germ cell tumors. We identified nine studies, including 101 patients; 33 patients (33%) were alive 12 months post-initial relapse. Sixty percent of patients with serum/cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) level ≤25 ng/mL at initial diagnosis were survivors compared with 28% among patients with serum/CSF AFP level >25 ng/mL (P = 0. Read More

View Article and Full-Text PDF
January 2022

Rapidly Enlarging Neck Mass in a Patient With Testicular Cancer.

JAMA Otolaryngol Head Neck Surg 2021 11;147(11):1001-1002

Department of Otolaryngology-Head and Neck Surgery, Tufts Medical Center, Boston, Massachusetts.

View Article and Full-Text PDF
November 2021

Contrast-enhanced ultrasound as a valuable imaging modality for characterizing testicular lesions.

Asian J Androl 2022 Mar-Apr;24(2):201-206

Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China.

Contrast-enhanced ultrasound (CEUS) is a new form of ultrasound (US) that can dynamically display microvessels in a highly sensitive manner. The purpose of this study was to investigate the efficacy of CEUS for characterizing testicular lesions in comparison with conventional US. Forty-seven patients with testicular lesions were enrolled. Read More

View Article and Full-Text PDF

Testicular Germ-Cell Tumors with Spermatic Cord Involvement: A Retrospective International Multi-Institutional Experience.

Mod Pathol 2022 02 9;35(2):249-255. Epub 2021 Sep 9.

Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.

The 8th Edition of the American Joint Committee on Cancer (AJCC) Staging Manual designates discontinuous involvement of spermatic cord soft tissue by testicular germ cell tumors as a metastatic deposit. We conducted a retrospective international multi-institutional study to validate the current recommendations. Thirty-three (72%) nonseminomatous and 13 (28%) seminomatous testicular germ cell tumors were collected from 15 institutions in America, Europe, and Asia. Read More

View Article and Full-Text PDF
February 2022

The absence of spermatogenesis in radical orchiectomy specimen is associated with advanced-stage nonseminomatous testicular cancer.

Urol Oncol 2021 12 2;39(12):838.e15-838.e20. Epub 2021 Sep 2.

Department of Urology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:

Background: To assess if clinical, pathological, and spermatogenesis factors are associated with clinical staging in patients with testicular germ cell tumors.

Patients And Methods: We retrospectively reviewed the pathology reports and slides from 267 men who underwent radical orchiectomy for testicular cancer at our institution during 1998-2019. Histologic slides were reviewed and the presence of mature spermatozoa was documented. Read More

View Article and Full-Text PDF
December 2021

Cutaneous nonseminomatous mixed extragonadal germ cell tumor: a case report.

Int J Dermatol 2022 Apr 9;61(4):e125-e126. Epub 2021 Aug 9.

Departamento de Dermatologia e Radioterapia, FMB-UNESP, Botucatu, SP, Brazil.

View Article and Full-Text PDF